Intellia Therapeutics Inc (NTLA) — Cash Flow Reinvestment Rate

Latest as of June 2020: 1.66x

Intellia Therapeutics Inc (NTLA) has a Cash Flow Reinvestment Rate of 1.66x as of June 2020, reinvesting $95.03 Million (capex $1.04 Million plus investments $94.00 Million) from operating cash flow of $57.42 Million. Explore cash efficiency ratio of Intellia Therapeutics Inc to assess how effectively this company generates cash.

Reinvestment Rate

1.66x

(Capex + Investments) / Operating CF

Total Reinvested

$95.03 Million

Capex + Investments

Operating Cash Flow

$57.42 Million

USD

Capital Expenditures

$1.04 Million

USD

Intellia Therapeutics Inc Cash Flow Reinvestment Rate (2016–2016)

Historical reinvestment intensity for Intellia Therapeutics Inc across 1 annual periods. Explore Intellia Therapeutics Inc (NTLA) investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Intellia Therapeutics Inc (2016–2016)

Year-by-year capital reinvestment analysis for Intellia Therapeutics Inc. For live market cap and broader valuation context, see Intellia Therapeutics Inc market capitalisation.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2016	0.34x	$12.33 Million	$36.11 Million	$6.17 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow